What is Engine Biosciences?
Engine Biosciences is a pioneering biotechnology company established in 2014, dedicated to revolutionizing drug discovery. By integrating advanced machine learning techniques with deep genomics expertise, the company aims to identify and develop novel therapeutic candidates more efficiently. Headquartered in Singapore, Engine Biosciences is strategically positioned to leverage global scientific talent and resources, driving innovation in a highly competitive sector. The company's approach focuses on accelerating the preclinical stages of drug development, a critical bottleneck in bringing new medicines to market.
How much funding has Engine Biosciences raised?
Engine Biosciences has raised a total of $88M across 3 funding rounds:
Angel/Seed
$10M
Other Financing Round
$18M
Series A
$60M
Angel/Seed (2018): $10M, investors not publicly disclosed
Other Financing Round (2023): $18M led by EDBI and Polaris Partners
Series A (2023): $60M supported by Dimensions Capital, Goodman Capital, Baidu Ventures, Nest.Bio, DHVC, WuXi AppTec, Polaris Partners, WI Harper Group, Invus, Vectr Ventures, and EDBI
Key Investors in Engine Biosciences
Dimensions Capital
Dimensions Capital is an investment company established in 2017, focusing on innovative life science companies with operations in China and the United States.
Baidu Ventures
Baidu Ventures, established in 2017, is an independent venture fund focused on artificial intelligence, investing in companies at the forefront of AI innovation, including computational genetics and precision medicine.
Nest.Bio
Nest.Bio is a research, development, and venture firm dedicated to transforming breakthrough life sciences and healthcare technologies into revolutionary companies.
What's next for Engine Biosciences?
With the recent infusion of $60M in a major strategic investment, Engine Biosciences is poised for significant expansion and operational scaling. This capital injection, part of a larger $88M funding initiative, will likely fuel advancements in their proprietary AI-driven drug discovery platform. The company is expected to enhance its research capabilities, expand its team of scientists and engineers, and potentially forge new strategic partnerships within the pharmaceutical and biotech industries. This sustained financial backing signals strong investor confidence in Engine Biosciences's long-term vision and its potential to disrupt traditional drug discovery paradigms.
See full Engine Biosciences company page
